Medicine and Health Sciences Commons^™

A Requirement For Slc15a4 In Imiquimod-Induced Systemic Inflammation And Psoriasiform Inflammation In Mice, Alexis D. Griffith, Asifa K. Zaidi, Ashley Pietro, Matthew Hadiono, Jessica S. Yang, Rachel Davis, Daniel L. Popkin

Faculty Publications

There is competing evidence that plasmacytoid dendritic cells (pDC), the most potent source of IFN-I, may initiate psoriasis. We targeted pDC function using the slc15a4 loss-of-function mouse whose pDC are unresponsive to TLR agonists. slc15a4 treated with the topical TLR7-agonist imiquimod (IMQ) demonstrated decreased epidermal thickening 24 hours post-treatment which was more pronounced by day 5 as compared to wildtype mice. These findings were specific to the acute IMQ model and not the protracted IL23 model that drives inflammation downstream of TLR activation. Systemically, slc15a4 was required for IMQ-induced weight loss and cutaneous accumulation of CD4+ and Siglec H+, but …